NewAmsterdam Pharma Company N.V. $NAMS Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC trimmed its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 822,300 shares of the company’s stock after selling 15,068 shares during the period. TimesSquare Capital Management LLC owned 0.73% of NewAmsterdam Pharma worth $28,846,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Capital World Investors boosted its position in NewAmsterdam Pharma by 17.1% during the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after purchasing an additional 1,434,986 shares during the period. Jennison Associates LLC boosted its position in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the period. Wellington Management Group LLP boosted its position in NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after purchasing an additional 697,129 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in NewAmsterdam Pharma by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after buying an additional 1,062,359 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its position in NewAmsterdam Pharma by 15.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock valued at $82,807,000 after buying an additional 393,855 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on NAMS. Royal Bank Of Canada upped their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research report on Thursday, February 19th. Truist Financial began coverage on shares of NewAmsterdam Pharma in a research report on Wednesday, March 18th. They issued a “buy” rating and a $57.00 price objective for the company. Guggenheim upped their price objective on shares of NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, February 19th. Finally, Needham & Company LLC upped their price objective on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Moderate Buy” and a consensus target price of $48.00.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock opened at $34.14 on Tuesday. The firm has a market cap of $3.99 billion, a PE ratio of -19.07 and a beta of 0.02. The firm’s 50-day simple moving average is $32.41 and its 200-day simple moving average is $34.30. NewAmsterdam Pharma Company N.V. has a 1 year low of $16.78 and a 1 year high of $42.21.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Tuesday, March 31st. The company reported ($0.40) earnings per share (EPS) for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative net margin of 943.23% and a negative return on equity of 26.49%. On average, equities analysts predict that NewAmsterdam Pharma Company N.V. will post -1.76 earnings per share for the current year.

Insider Activity

In other news, insider Johannes Jacob Piete Kastelein sold 101,409 shares of the company’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $30.29, for a total value of $3,071,678.61. Following the sale, the insider owned 69,302 shares in the company, valued at approximately $2,099,157.58. This represents a 59.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael H. Davidson sold 443,707 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $33.25, for a total transaction of $14,753,257.75. Following the completion of the sale, the chief executive officer owned 174,144 shares in the company, valued at approximately $5,790,288. This trade represents a 71.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 1,168,286 shares of company stock worth $38,211,967. 12.74% of the stock is currently owned by corporate insiders.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.